Search Results - "Norton, Miranda"

A New Liquid 10% Intravenous Immunoglobulin (IVIG) Administered with 15-Minute Titration Periods Allows Shorter Infusion Durations and Tolerability Similar to a 5% Formulation by Stein, Mark R., Dr, Farnan, Kelly, Ms, Eufrasio, Danielle, Ms, Norton, Miranda, Dr

“…Methods GMX07 (NCT01963143) was a phase 3, multicenter, open-label, randomized, 2-period, crossover bioequivalence trial that evaluated the pharmacokinetics,…”
Get full text

Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study by Öner, Ahmet F, Celkan, Tiraje, Timur, Çetin, Norton, Miranda, Kavaklı, Kaan

“…Hereditary factor X (FX) deficiency is a rare bleeding disorder more prevalent in countries with high rates of consanguineous marriage. In a prospective,…”
Get full text

Plasma Derived Factor X Concentrate Has Not Induced Inhibitor Development in the Clinical Setting by Patel, Hitan, Norton, Miranda, Lewandowska, Magdalena D.

Get full text

Analysis of trough levels of total IgG, IgG subclasses, measles neutralizing antibodies and IgG antibodies to encapsulated pathogens after infusion of a 5% or 10% intravenous immunoglobulin by Clark, Kim, Norton, Miranda, Paddick, Martyn, More, John

“…Patients with primary immunodeficiency (PI) are at risk of infection due to low IgG levels. We report trough levels of total IgG, IgG subclasses, measles…”
Get full text

Genotype Analysis of Patients with Hereditary Factor X Deficiency Enrolled in 2 Phase 3 Studies of Pdfx, a New High-Purity Factor X Concentrate by Mitchell, Mike, Kavakli, Kaan, Norton, Miranda, Austin, Steve

“…Introduction: Hereditary factor X (FX) deficiency is a rare, autosomal recessive bleeding disorder of variable severity, with an estimated prevalence of…”
Get full text

Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency by Mitchell, Michael, Gattens, Michael, Kavakli, Kaan, Liesner, Ri, Payne, Jeanette, Norton, Miranda, Austin, Steven

“…The objective was to examine the genotypic and phenotypic characteristics of individuals with hereditary factor X deficiency (FXD), a rare autosomal recessive…”
Get full text

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex^sup ^ 10% Versus Gammaplex^sup ^ 5% in Subjects with Primary Immunodeficiency by Wasserman, Richard L, Melamed, Isaac R, Stein, Mark R, Jolles, Stephen, Norton, Miranda, Moy, James N

“…Purpose This phase 3, multicenter, open-label, randomized, two-period, crossover bioequivalence trial evaluated the safety, tolerability, and pharmacokinetics…”
Get full text

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency by Wasserman, Richard L., Melamed, Isaac R., Stein, Mark R., Jolles, Stephen, Norton, Miranda, Moy, James N.

“…Purpose This phase 3, multicenter, open-label, randomized, two-period, crossover bioequivalence trial evaluated the safety, tolerability, and pharmacokinetics…”
Get full text

Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency by Wasserman, Richard L., Melamed, Isaac R., Stein, Mark R., Jolles, Stephen, Norton, Miranda, Moy, James N.

Get full text